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LETTERS
Hemolytic uremic syndrome occurs
in approximately 8% of children and
an unknown proportion of adults
infected with E. coli O157 and can be
fatal without hemodialysis. The high
death rate of infants during this out-
break was linked to the lack of treat-
ment (mainly hemodialysis) at the
beginning of the epidemic.
Obviously, more work is needed to
better define the incidence and epi-
demiology of E. coli–associated diar-
rhea in the Democratic Republic of
Congo so that optimal recommenda-
tions for preventing and managing ill-
ness can be developed.
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Iatrogenic
Mycobacterium
simiae Skin
Infection in an
Immunocompetent
Patient 
To the Editor: We report a case of
a 36-year-old woman who sought
treatment for 45 firm and erythema-
tous nodular lesions on her face and
neck. A physical examination showed
no other abnormalities. Results of a
chest x-ray and routine laboratory
tests were normal. The patient tested
negative for hepatitis B and HIV.
Three weeks before she sought treat-
ment, the patient reported receiving
multiple intradermal microinjections
in her face and neck for cosmetic pur-
poses (mesotherapy) with an unli-
censed product consisting of a solu-
tion of glycosaminoglycans. The
injections had been administered by
an unlicensed practitioner in a non-
medical office setting. The patient
stated that 2 days after the therapy, a
fever developed; it persisted for sev-
eral days, along with redness at the
inoculation sites, which gradually
developed into nodules. 
Standard staining of a biopsied
specimen from the lesion site was
negative for bacteria, fungi, and
mycobacteria. A histopathologic
examination of a biopsy specimen
showed an unspecific granulomatous
infiltrate. Culture for common bacte-
ria and fungi was negative, but culture
of a sterile nodule aspirate on
Lowenstein-Jensen medium was posi-
tive for acid-fast bacteria after 5
weeks. By using restriction endonu-
clease analysis of the 65-kDa heat
shock protein gene (1), we found that
the isolate showed a pattern compati-
ble with Mycobacterium simiae.
Identification was subsequently con-
firmed by high performance liquid
chromatography of mycolic acids at
the Centers for Disease Control and
Prevention, Atlanta, Georgia. The iso-
late was tested for drug susceptibility
against a panel of drugs and found to
be resistant to most drugs tested
(streptomycin, isoniazid, rifampin,
ethambutol, ethionamide, rifabutin,
ciprofloxacin, kanamycin, capre-
omycin, p-aminosalicylic acid,
ofloxacin, and amikacin) and suscep-
tible to clarithromycin at an MIC of 1
µg/mL. Treatment with clar-
ithromycin was started, and the gran-
ulomas slowly cleared after 9 months
of treatment. 
To our knowledge, this is the first
reported case of an iatrogenic skin
infection caused by M. simiae in an
immunocompetent person. M. simiae
is a species of nontuberculous
mycobacterium commonly found in
nature, but its role as a pathogen has
been controversial. The slow-grow-
ing, photochromogenic mycobacteri-
um has been isolated from both sur-
face and tap water and has been asso-
ciated with a nosocomial pseudo-out-
break suspected to have originated
from a contaminated hospital water
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supply (2). M. simiae  rarely causes
disease in immunocompetent patients;
most infections are associated with
AIDS patients. (3–5). 
Although this patient responded to
treatment with clarithromycin, no
established optimal therapeutic regi-
men exists against this species of
Mycobacterium. M. simiae is often
multidrug resistant, but successful
therapy with clarithromycin in combi-
nation with ethambutol and
ciprofloxacin has been reported in
AIDS patients (6,7).
We conclude that M. simiae can
cause skin infections if injected direct-
ly into the dermis. Prolonged treat-
ment is necessary to cure the patient of
the infection. This report underscores
the risk from alternative therapies per-
formed with unlicensed products and
by unlicensed practitioners. Unusual
infectious agents should be considered
when diagnosing skin infection in
patients who have received injections
for cosmetic purposes.
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